634 related articles for article (PubMed ID: 17686008)
1. Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors.
Kumamoto H; Ooya K
J Oral Pathol Med; 2007 Sep; 36(8):488-94. PubMed ID: 17686008
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of insulin-like growth factors, platelet-derived growth factor, and their receptors in ameloblastic tumors.
Kumamoto H; Ooya K
J Oral Pathol Med; 2007 Apr; 36(4):198-206. PubMed ID: 17391297
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical detection of MT1-MMP, RECK, and EMMPRIN in ameloblastic tumors.
Kumamoto H; Ooya K
J Oral Pathol Med; 2006 Jul; 35(6):345-51. PubMed ID: 16762015
[TBL] [Abstract][Full Text] [Related]
4. Expression of bone morphogenetic proteins and their associated molecules in ameloblastomas and adenomatoid odontogenic tumors.
Kumamoto H; Ooya K
Oral Dis; 2006 Mar; 12(2):163-70. PubMed ID: 16476038
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of platelet-derived endothelial cell growth factor/thymidine phosphorylase and angiopoietins in ameloblastic tumors.
Kumamoto H; Ooya K
J Oral Pathol Med; 2006 Nov; 35(10):606-12. PubMed ID: 17032393
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical detection of phosphorylated JNK, p38 MAPK, and ERK5 in ameloblastic tumors.
Kumamoto H; Ooya K
J Oral Pathol Med; 2007 Oct; 36(9):543-9. PubMed ID: 17850438
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical detection of phosphorylated Akt, PI3K, and PTEN in ameloblastic tumors.
Kumamoto H; Ooya K
Oral Dis; 2007 Sep; 13(5):461-7. PubMed ID: 17714348
[TBL] [Abstract][Full Text] [Related]
8. Detection of CD133, Bmi-1, and ABCG2 in ameloblastic tumors.
Kumamoto H; Ohki K
J Oral Pathol Med; 2010 Jan; 39(1):87-93. PubMed ID: 19659474
[TBL] [Abstract][Full Text] [Related]
9. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
[TBL] [Abstract][Full Text] [Related]
10. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
13. Detection of mitochondria-mediated apoptosis signaling molecules in ameloblastomas.
Kumamoto H; Ooya K
J Oral Pathol Med; 2005 Oct; 34(9):565-72. PubMed ID: 16138896
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of BH3-only proteins in ameloblastic tumors.
Kumamoto H; Ooya K
Oral Dis; 2008 Sep; 14(6):550-5. PubMed ID: 18826384
[TBL] [Abstract][Full Text] [Related]
15. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract][Full Text] [Related]
16. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
17. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
18. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson SR; Casslén B
Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126
[TBL] [Abstract][Full Text] [Related]
19. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
20. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Taponeco F; Curcio C; Giuntini A; Nardini V; Fornaciari G; Artini PG; D'Ambrogio G; Genazzani AR
J Exp Clin Cancer Res; 2001 Jun; 20(2):239-46. PubMed ID: 11484981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
